Biogen (BIIB) stock slides after the company issued a weak 2025 outlook. Super Micro Computer (SMCI) shares gain on upbeat long-term outlook despite recent challenges. Stay up to date on the ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

With many of the elite stocks technically overbought after huge moves in late 2023 and early 2024, we've done a search for stocks that might provide some 'alpha' if the red-hot AI stocks finally ...

Canaccord lowered the firm’s price target on Biogen (BIIB) to $265 from $298 and keeps a Buy rating on the shares. The firm noted the market was less than enthusiastic about BIIB’s 2025E ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 results. The company has successfully reprioritized R&D ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Biogen posted Q4 adjusted EPS of $3.44, up 17%, beating the $3.35 consensus. Sales rose to $2.46B, surpassing estimates. Biogen forecasts 2025 EPS of $15.25-$16.25, below the $16.34 consensus ...